| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC20108 | Afegostat D-Tartrate (D-Isofagomine (D-Tartrate); Isofagomine (D-Tartrate)) | Afegostat D-Tartrate is a pharmacological chaperone, which specifically and reversibly binds acid-β-glucosidase (GCase) in the endoplasmic reticulum (ER) with high affinity. |
|
| DC9026 | Afloqualone | Afloqualone is a agonist of GABA receptor . |
|
| DC10513 | AFN-1252(Debio 1452) Featured | AFN-1252(Debio 1452) is a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibited all clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis at concentrations of ≤0.12 μg/ml. |
|
| DC9764 | Afoxolaner Featured | Afoxolaner is an isoxazoline that inhibits insect and acarine ligand-gated chloride channels, in particular those gated by the neurotransmitter gamma-aminobutyric acid (GABA), blocking pre and post synaptic transfer of chloride ions across cell membranes. |
|
| DC10844 | Aftin-4 Featured | Aftin-4, an amyloid forty-two inducer, activates γ-secretase, promoting the generation of amyloid-β-1-42 (Aβ1-42) from amyloid-β protein precursor. |
|
| DC7994 | Afuresertib HCl Featured | Afuresertib (GSK2110183) is a potent pan-AKT inhibitor that demonstrated synergy with bortezomib in preclinical models of multiple myeloma (MM). |
|
| DC8411 | Afuresertib Featured | Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2. |
|
| DC10589 | AG 1406 Featured | AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 . |
|
| DC8051 | AG-120 (Ivosidenib) Featured | AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein. |
|
| DC8507 | AG13958 | AG13958 is a VEGF inhibitor that was clinical development by Pfizer in 2006-07 for treatment of age-related macular degeneration (AMD). |
|
| DC5106 | AG14361 Featured | AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM. It is at least 1000-fold more potent than the benzamides. |
|
| DC1078 | AG-1478 (Tyrphostin AG-1478) Featured | AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM. |
|
| DC8079 | AG-1557 Featured | AG-1557 is an ultra-potent inhibitor of epidermal growth factor receptor tyrosine kinase (EGFRK). |
|
| DC1080 | Tyrphostin 9（AG-17） Featured | AG-17 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431. |
|
| DC7051 | AG-18 Featured | AG-18(RG-50810; Tyrphostin A23) inhibits EGFR with IC50 of 40 μM. |
|
| DC8374 | AG-221(Enasidenib) Featured | AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein. |
|
| DC7164 | AG-024322 | AG-24322 is a second generation CDK inhibitor. AG-024322 is a potent inhibitor of CDK1, CDK2, and CDK4 that produces cell-cycle arrest and antitumor activity in preclinical models. The no-adverse-effect dose of AG-024322 was 2 mg/kg and associated with ov |
|
| DC12499 | AG-270 Featured | AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM. |
|
| DC2096 | AG490 Featured | AG-490 (Tyrphostin B42) is an inhibitor of EGFR, ErbB2 and JAK2 with IC50 of 0.1 μM, 13.5 μM, and ~10 μM, respectively. |
|
| DC10623 | AG-494 Featured | AG-494 is an inhibitor of epidermal growth factor receptor kinase with an IC50 value of 1 µM in HT-22 cells. |
|
| DC10439 | Vorasidenib (AG881) Featured | AG-881 is a potent and selective orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1) in the cytoplasm and type 2 (IDH2). |
|
| DC12382 | AG-99 Featured | AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431. |
|
| DC12196 | Aganepag (AGN 210937) | Aganepag is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM, and shows no activity at EP4 receptor. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention. |
|
| DC21990 | AGI-14100 | AGI-14100 (AGI14100) is a novel potent and selective, orally available IDH1 mutant inhibitor. |
|
| DC5050 | AGI-5198 Featured | AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM. |
|
| DC7174 | AGI-6780 Featured | AGI-6780 is the first highly potent and selective small molecule inhibitor of isocitrate dehydrogenases, which binds in an allosteric manner at the dimer interface of mutant IDH2-R140Q (IC50=23 nM). |
|
| DC8437 | AGK2 Featured | AGK2 is a potent, and selective SIRT2 inhibitor with IC50 of 3.5 μM. |
|
| DC12225 | AGL-2263 | AGL-2263 is an insulin receptor (IR) blocker. |
|
| DC7767 | AGN 194310 | AGN 194310(VTP-194310) is a potent and selective pan-RARs agonist with Kd values of 3/2/5 nM for RARα/β/γ respectively. |
|
| DC12213 | AGN 210676 (Simenepag) | AGN 210676 is a selective prostaglandin EP2 agonist extracted from patent US20070203222A1, Compound example 23, has an EC50 of 5 nM. |
|
